Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 4/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1728331 | 0.90 | TDP1 (0.54) | TSHRTDP1L3MBTL1MAOBMAOA | |
| SCHEMBL7369619 | 0.87 | TSHR (0.62) | TSHRMAOBMAOAALDH1A1CYP2A6 | |
| SCHEMBL14328706 | 0.83 | MAOA (0.58) | TSHRTDP1MAOBMAOAALDH1A1 | |
| SCHEMBL1066576 | 0.83 | TSHR (0.67) | TSHRTDP1L3MBTL1ALDH1A1CYP2A6 | |
| Hydrochloric Acid SCHEMBL1409425 | 0.81 | TSHR (0.64) | TSHRTDP1L3MBTL1MAOBMAOA | |
| Water SCHEMBL28780406 | 0.81 | TSHR (0.64) | TSHRTDP1L3MBTL1ALDH1A1RAB9A | |
| SCHEMBL2226596 | 0.81 | ALDH1A1 (0.59) | TDP1MAOBMAOAALDH1A1CYP2A6 | |
| SCHEMBL14369268 | 0.81 | ALDH1A1 (0.59) | TDP1MAOBMAOAALDH1A1CYP2A6 | |
| SCHEMBL8806830 | 0.81 | RAB9A (0.60) | MAOBMAOAALDH1A1RAB9ALTA4H | |
| SCHEMBL4758428 | 0.80 | SMN1; SMN2 (0.51) | TSHRMAOBMAOAALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324176-B2 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| EP-1548024-B1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-7635684-B2 | treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. -[(4-{3-[N-(Carbamoylmethyl)-N-(methanesulfonyl)amino]-propoxy}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-22 | — | — | US | disclosed |
| US-20090203633-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL CO., LTD (JP) | 2009-08-13 | — | — | US | disclosed |
| CN-100413878-C | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL COMPANY (JP) | 2008-08-27 | — | — | CN | disclosed |
| CN-1835934-A | oxazole derivatives as cyclooxygenase inhibitors | ASTELLAS PHARMA INC (JP) | 2006-09-20 | — | — | CN | disclosed |
| US-20050272669-A1 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-12-08 | — | — | US | disclosed |
| CN-1688597-A | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL COMPANY (JP) | 2005-10-26 | — | — | CN | disclosed |
| EP-1583749-A1 | OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE | Astellas Pharma Inc. (JP) | 2005-10-12 | — | — | EP | disclosed |
| EP-1548024-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| WO-2004065374-A1 | OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE | ASTELLAS PHARMA INC. (JP) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203633-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | UGGT1, GCKR, SLC5A1 | TSHR 665/4885TDP1 4297/4885L3MBTL1 745/4885 |
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | TSHR 4439/4885TDP1 3717/4885L3MBTL1 4432/4885 |
| US-20050272669-A1 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | UGGT1, GCKR, SLC5A1 | TSHR 665/4885TDP1 4297/4885L3MBTL1 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.